Concepedia

Barbara DeLange

BD

3

Publications

138

Citations

3

H-Index

1990

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Barbara DeLange is an author at Bristol-Myers Squibb (United States) specializing in medicinal chemistry, natural sciences, and pharmacology.

Top concepts

BiochemistryPharmacologyNatural SciencesMedicinal ChemistryMedicineBiosynthesisDrug DiscoveryChemical BiologyMolecular PharmacologyChemistry

Publications per year

1990–1991

3

Publications

3

The first potent inhibitor of squalene synthase: a profound contribution of an ether oxygen to inhibitor-enzyme interaction

Scott A. Biller, Michael J. Sofia, Barbara DeLange et al. · Journal of the American Chemical Society · 1991 · 76 citations

Pharmaceutical Science, Organic Chemistry, Chemical Biology +19

Phosphorus-containing inhibitors of HMG-CoA reductase. I. 4-[(2-Arylethyl)hydroxyphosphinyl]-3-hydroxybutanoic acids: a new class of cell selective inhibitors of cholesterol biosynthesis

Donald S. Karanewsky, Michael C. Badia, Carl P. Ciosek et al. · Journal of Medicinal Chemistry · 1990 · 51 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biosynthesis +14

ChemInform Abstract: Phosphorus‐Containing Inhibitors of HMG‐CoA Reductase. Part 1. 4‐((2‐ Arylethyl)hydroxyphosphinyl)‐3‐hydroxybutanoic Acids: A New Class of Cell‐Selective Inhibitors of Cholesterol Biosynthesis.

Donald S. Karanewsky, Michael C. Badia, Carl P. Ciosek et al. · ChemInform · 1991 · 11 citations

Cholesterol Biosynthesis, Medicinal Chemistry, Biosynthesis +11

Rows per page

1–3 of 3